Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Revenue of Aura Biosciences, Inc. (AURA)
Revenue in 2023 (TTM): $
According to Aura Biosciences, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Aura Biosciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-1,295,000 | $-83,696,000 | $-76,271,000 | $-76,408,000 |
| 2022 | $ | $-1,177,000 | $-59,118,000 | $-58,763,000 | $-57,231,000 |
| 2021 | $ | $-835,000 | $-34,416,000 | $-35,251,000 | $-34,421,000 |
| 2020 | $ | $-831,000 | $-21,375,000 | $-22,206,000 | $-22,209,000 |
| 2019 | $ | $-509,000 | $-23,631,000 | $-24,200,000 | $-24,205,000 |